🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Placebo NDPI

Found 14 matching trials

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in ...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-05

Trial ID

NCT01868009

Treatments Being Tested

ELLIPTA DISKUS

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-04-04

Trial ID

NCT01822899

Treatments Being Tested

Umeclidinium bromide/Vilanterol Placebo ACCUHALER/DISKUS Fluticasone propionate/Salmeterol Placebo NDPI

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

PHASE3

The objective of this study is to evaluate the efficacy and safety of vilan...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-09-01

Trial ID

NCT01181895

Treatments Being Tested

Vilanterol Salmeterol Inhalation Powder Placebo Inhalation Powder NDPI Placebo Inhalation Powder Diskus

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this 52-week study is to evaluate the long-term safety (in t...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-01-01

Trial ID

NCT01316887

Treatments Being Tested

125/25 mcg once-daily GSK573719/GW642444 125mcg once-daily GSK573719 Placebo once-daily

Efficacy and Safety Study in Subjects With Asthma

PHASE2

The study is a multi-center, double-blind, placebo-controlled, cross-over s...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-09

Trial ID

NCT00980200

Treatments Being Tested

Dose 4 QD Dose 3 QD placebo Dose 2 QD Dose 1 BD

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This is a multicenter, randomized, double-blind, double-dummy, parallel gro...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-03-01

Trial ID

NCT01817764

Treatments Being Tested

Umeclidinium/vilanterol Fluticasone propionate/salmeterol Placebo

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This will be a Phase IIIb multicentre, randomized, double-blind, double-dum...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-10-15

Trial ID

NCT01706328

Treatments Being Tested

FF/VI 100/25 Inhalation Powder NDPI Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS Placebo Inhalation Powder NDPI Placebo Inhalation Powder ACCUHALER/DISKUS Salbutamol as needed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

Umeclidinium/vilanterol (UMEC/VI) is a combination product under developmen...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-06-13

Trial ID

NCT01879410

Treatments Being Tested

UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS Placebo DISKUS Placebo NDPI

Previous Next